Archives of Advances in Biosciences

[1] Lolli F, Pallotti F, Rossi A, Fortuna MC, Caro G, Lenzi A, et al. Androgenetic alopecia: a review. Endocrine. 2017;57(1):9-17. [DOI: 10.1007/s12020-017-1280-y] [PMID]

[2] Yip L, Zaloumis S, Irwin D, Severi G, Hopper J, Giles G, et al. Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. Br J Dermatol. 2009;161(2):289-94. [DOI: 10.1111/j.1365-2133.2009.09186.x] [PMID]

[3] Otberg N, Finner AM, Shapiro J. Androgenetic alopecia. Endocrinol Metab Clin North Am. 2007;36(2):379-98. [DOI: 10.1016/j.ecl.2007.03.004] [PMID]

[4] Almohanna HM, Perper M, Tosti A. Safety concerns when using novel medications to treat alopecia. Expert Opin Drug Saf. 2018;17(11):1115-28. [DOI: 10.1080/14740338.2018.1533549] [PMID]

[5] Erratum. Expert Opin Emerg Drugs. 2015;20(2):347. [DOI: 10.1517/14728214.2015.1027860] [PMID]

[6] Vañó-Galván S, Camacho F. Novedades terapéuticas en tricología. Actas Dermosifiliogr. 2017;108(3):221-8. [DOI: 10.1016/j.ad.2016.11.010] [PMID]

[7] Bienenfeld A, Azarchi S, Lo Sicco K, Marchbein S, Shapiro J, Nagler AR. Androgens in women: androgen-mediated skin disease and patient evaluation. J Am Acad Dermatol. 2019;80(6):1497-506. [DOI: 10.1016/j.jaad.2018.08.062] [PMID]

[8] Sadick NS, Callender VD, Kircik LH, Kogan S. New insight into the pathophysiology of hair loss trigger a paradigm shift in the treatment approach. J Drugs Dermatol. 2017;16(11):s135-40. [LINK]

[9] Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med. 1999;341(7):491-7. [DOI: 10.1056/NEJM199908123410706] [PMID]

[10] Hardy MH. The secret life of the hair follicle. Trends Genet. 1992;8(2):55-61. [DOI: 10.1016/0168-9525(92)90350-D]

[11] Hoover E, Alhajj M, Flores JL. Physiology, hair. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026. Updated 2023 Jul 30. [LINK]

[12] Park AM, Khan S, Rawnsley J. Hair biology: growth and pigmentation. Facial Plast Surg Clin North Am. 2018;26(4):415-24. [DOI: 10.1016/j.fsc.2018.06.003] [PMID]

[13] Natarelli N, Gahoonia N, Sivamani RK. Integrative and mechanistic approach to the hair growth cycle and hair loss. J Clin Med. 2023;12(3):893. [DOI: 10.3390/jcm12030893] [PMID]

[14] Stenn KS, Paus R. Controls of hair follicle cycling. Physiol Rev. 2001;81(1):449-94. [DOI: 10.1152/physrev.2001.81.1.449] [PMID]

[15] Grymowicz M, Rudnicka E, Podfigurna A, Napierala P, Smolarczyk R, Smolarczyk K, et al. Hormonal effects on hair follicles. Int J Mol Sci. 2020;21(15):5342. [DOI: 10.3390/ijms21155342] [PMID]

[16] Ohnemus U, Uenalan M, Inzunza J, Gustafsson JA, Paus R. The hair follicle as an estrogen target and source. Endocr Rev. 2006;27(6):677-706. [DOI: 10.1210/er.2006-0020] [PMID]

[17] Truong AT, Duez C, Belayew A, Renard A, Pictet R, Bell GI, et al. Isolation and characterization of the human prolactin gene. EMBO J. 1984;3(2):429-37. [DOI: 10.1002/j.1460-2075.1984.tb01824.x] [PMID]

[18] Martinet L, Allain D, Weiner C. Role of prolactin in the photoperiodic control of moulting in the mink (Mustela vison). J Endocrinol. 1984;103(1):9-15. [DOI: 10.1677/joe.0.1030009] [PMID]

[19] Bodó E, Kromminga A, Bíró T, Borbíró I, Gáspár E, Zmijewski MA, et al. Human female hair follicles are a direct, nonclassical target for thyroid-stimulating hormone. J Invest Dermatol. 2009;129(5):1126-39. [DOI: 10.1038/jid.2008.361] [PMID]

[20] Slominski A, Tobin DJ, Zmijewski MA, Wortsman J, Paus R. Melatonin in the skin: synthesis, metabolism and functions. Trends Endocrinol Metab. 2008;19(1):17-24. [DOI: 10.1016/j.tem.2007.10.007] [PMID]

[21] Janjetovic Z, Jarrett SG, Lee EF, Duprey C, Reiter RJ, Slominski AT. Melatonin and its metabolites protect human melanocytes against UVB-induced damage: involvement of NRF2-mediated pathways. Sci Rep. 2017;7(1):1274. [DOI: 10.1038/s41598-017-01305-2] [PMID]

[22] Xiang L, Sunesara I, Rehm KE, Marshall GD Jr. Hair cortisol concentrations are associated with hair growth rate. Neuroimmunomodulation. 2016;23(5-6):287-94. [DOI: 10.1159/000455867] [PMID]

[23] Stoehr JR, Choi JN, Colavincenzo M, Vanderweil S. Off-label use of topical minoxidil in alopecia: a review. Am J Clin Dermatol. 2019;20(2):237-50. [DOI: 10.1007/s40257-018-0409-y] [PMID]

[24] Rossi A, Cantisani C, Melis L, Iorio A, Scali E, Calvieri S. Minoxidil use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012;6(2):130-6. [DOI: 10.2174/187221312800166859] [PMID]

[25] Fiedler-Weiss VC. Minoxidil. Dermatol Clin. 1987;5(3):627-35. [PMID]

[26] Rumsfield JA, West DP, Fiedler-Weiss VC. Topical minoxidil therapy for hair regrowth. Clin Pharm. 1987;6(5):386-92. [PMID]

[27] Katz HI. Topical minoxidil: review of efficacy and safety. Cutis. 1989;43(1):94-8. [PMID]

[28] Kvedar JC, Baden HP. Topical minoxidil in the treatment of male pattern alopecia. Pharmacotherapy. 1987;7(6):191-7. [DOI: 10.1002/j.1875-9114.1987.tb03523.x] [PMID]

[29] Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-85. [DOI: 10.1067/mjd.2002.124088] [PMID]

[30] Ghonemy S, Alarawi A, Bessar H. Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. J Dermatolog Treat. 2021;32(2):236-41. [DOI: 10.1080/09546634.2019.1654070] [PMID]

[31] Chandran NS, Oranje AP. Minoxidil 5% solution for topical treatment of loose anagen hair syndrome. Pediatr Dermatol. 2014;31(3):389-90. [DOI: 10.1111/pde.12307] [PMID]

[32] Panchaprateep R. Medical treatment for androgenetic alopecia. Facial Plast Surg. 2024;40(2):252-66. [DOI: 10.1055/a-2196-4713] [PMID]

[33] Headington JT. Hair follicle biology and topical minoxidil: possible mechanisms of action. Dermatologica. 1987;175 Suppl 2:19-22. [DOI: 10.1159/000248894] [PMID]

[34] Friedman ES, Friedman PM, Cohen DE, Washenik K. Allergic contact dermatitis to topical minoxidil solution: etiology and treatment. J Am Acad Dermatol. 2002;46(2):309-12. [DOI: 10.1067/mjd.2002.119104] [PMID]

[35] El Anzi O, Hassam B. Pustular dermatosis of the scalp due to topical minoxidil 5%. Pan Afr Med J. 2018;30:83. [DOI: 10.11604/pamj.2018.30.83.15384] [PMID]

[36] Kiratiwongwan R, Boonchai W, Kanokrungsee S. Allergic contact dermatitis to topical preparations containing minoxidil: a systematic review and individual participant data meta-analysis. Dermatitis. 2025;36(3):200-6. [DOI: 10.1089/derm.2024.0092] [PMID]

[37] Hagemann T, Schlütter-Böhmer B, Allam JP, Bieber T, Novak N. Positive lymphocyte transformation test in a patient with allergic contact dermatitis of the scalp after short-term use of topical minoxidil solution. Contact Dermatitis. 2005;53(1):53-5. [DOI: 10.1111/j.0105-1873.2005.00456b.x] [PMID]

[38] Claudet I, Cortey C, Honorat R, Franchitto N. Minoxidil topical solution: an unsafe product for children. Pediatr Emerg Care. 2015;31(1):44-6. [DOI: 10.1097/PEC.0000000000000301] [PMID]

[39] Jordan TJ, Yaxley PE, Culler CA, Balakrishnan A. Successful management of minoxidil toxicosis in a dog. J Am Vet Med Assoc. 2018;252(2):222-6. [DOI: 10.2460/javma.252.2.222] [PMID]

[40] McClellan KJ, Markham A. Finasteride: a review of its use in male pattern hair loss. Drugs. 1999;57(1):111-26. [DOI: 10.2165/00003495-199957010-00014] [PMID]

[41] Piraccini BM, Blume-Peytavi U, Scarci F, Jansat JM, Falqués M, Otero R, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022;36(2):286-94. [DOI: 10.1111/jdv.17738] [PMID]

[42] Lee SW, Juhasz M, Mobasher P, Ekelem C, Mesinkovska NA. A systematic review of topical finasteride in the treatment of androgenetic alopecia in men and women. J Drugs Dermatol. 2018;17(4):457-63. [PMID]

[43] Caserini M, Radicioni M, Leuratti C, Terragni E, Iorizzo M, Palmieri R. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. Int J Clin Pharmacol Ther. 2016;54(1):19-27. [DOI: 10.5414/CP202467] [PMID]

[44] Kim S, Eum J, Yang H, Jung H. Transdermal finasteride delivery via powder-carrying microneedles with a diffusion enhancer to treat androgenetic alopecia. J Control Release. 2019;316:1-11. [DOI: 10.1016/j.jconrel.2019.11.002] [PMID]

[45] Khan MZU, Khan SA, Ubaid M, Shah A, Kousar R, Murtaza G. Finasteride topical delivery systems for androgenetic alopecia. Curr Drug Deliv. 2018;15(8):1100-11. [DOI: 10.2174/1567201815666180124112905] [PMID]

[46] Than JK, Rodriguez K, Khera M. Post-finasteride syndrome: a review of current literature. Curr Sex Health Rep. 2018;10(3):152-7. [DOI: 10.1007/s11930-018-0163-4]

[47] Farkas HS, Jee YH, Szymczuk V, Leschek EW. Persistent gynecomastia due to short-term low-dose finasteride for androgenetic alopecia. JCEM Case Rep. 2024;2(5):luae050. [DOI: 10.1210/jcemcr/luae050] [PMID]

[48] Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011;8(6):1747-53. [DOI: 10.1111/j.1743-6109.2011.02255.x]

[49] Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J Clin Psychiatry. 2012;73(9):1220-3. [DOI: 10.4088/JCP.12m07887] [PMID]

[50] Irwig MS. Persistent sexual side effects of finasteride: could they be permanent? J Sex Med. 2012;9(11):2927-32. [DOI: 10.1111/j.1743-6109.2012.02846.x] [PMID]

[51] Traish AM. Post-finasteride syndrome: a surmountable challenge for clinicians. Fertil Steril. 2020;113(1):21-50. [DOI: 10.1016/j.fertnstert.2019.11.030] [PMID]

[52] Noor NM, Abdul-Aziz A, Sheikh K, Somavarapu S, Taylor KM. In vitro performance of dutasteride-nanostructured lipid carriers coated with lauric acid-chitosan oligomer for dermal delivery. Pharmaceutics. 2020;12(10):994. [DOI: 10.3390/pharmaceutics12100994]

[53] Oliveira PM, Alencar-Silva T, Pires FQ, Cunha-Filho M, Gratieri T, Carvalho JL, et al. Nanostructured lipid carriers loaded with an association of minoxidil and latanoprost for targeted topical therapy of alopecia. Eur J Pharm Biopharm. 2022;172:78-88. [DOI: 10.1016/j.ejpb.2022.02.003] [PMID]

[54] Herz-Ruelas ME, Álvarez-Villalobos NA, Millán-Alanís JM, León-Gutiérrez HD, Ocampo-Garza SS, Gómez-Flores M, et al. Efficacy of intralesional and oral dutasteride in the treatment of androgenetic alopecia: a systematic review. Skin Appendage Disord. 2020;6(6):338-45. [DOI: 10.1159/000510697] [PMID]

[55] Xu XG, Chen HD. Prostanoids and hair follicles: implications for therapy of hair disorders. Acta Derm Venereol. 2018;98(3):318-23. [DOI: 10.2340/00015555-2843] [PMID]

[56] Shin DW. The physiological and pharmacological roles of prostaglandins in hair growth. Korean J Physiol Pharmacol. 2022;26(6):405-13. [DOI: 10.4196/kjpp.2022.26.6.405] [PMID]

[57] Chovarda E, Sotiriou E, Lazaridou E, Vakirlis E, Ioannides D. The role of prostaglandins in androgenetic alopecia. Int J Dermatol. 2021;60(6):730-5. [DOI: 10.1111/ijd.15378] [PMID]

[58] Garza LA, Liu Y, Yang Z, Alagesan B, Lawson JA, Norberg SM, et al. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med. 2012;4(126):126ra34. [DOI: 10.1126/scitranslmed.3003122] [PMID]

[59] Ahluwalia GS. Safety and efficacy of bimatoprost solution 0.03% topical application in patients with chemotherapy-induced eyelash loss. J Investig Dermatol Symp Proc. 2013;16(1):S73-6. [DOI: 10.1038/jidsymp.2013.30] [PMID]

[60] Subedi L, Pandey P, Shim JH, Kim KT, Cho SS, Koo KT, et al. Preparation of topical bimatoprost with enhanced skin infiltration and in vivo hair regrowth efficacy in androgenic alopecia. Drug Deliv. 2022;29(1):328-41. [DOI: 10.1080/10717544.2022.2027046] [PMID]

[61] Barrón-Hernández YL, Tosti A. Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia. Expert Opin Investig Drugs. 2017;26(4):515-22. [DOI: 10.1080/13543784.2017.1303480] [PMID]

[62] Uno H, Zimbric ML, Albert DM, Stjernschantz J. Effect of latanoprost on hair growth in the bald scalp of the stump-tailed macacque: a pilot study. Acta Derm Venereol. 2002;82(1):7-12. [DOI: 10.1080/000155502753600803] [PMID]

[63] Razi-Khosroshahi MA, Sobhani S, Yousefi KM, Harooni G, Mashayekhi F, Balasi J, et al. Latanoprost in treatment of alopecia areata and androgenic alopecia: a comprehensive review. Pak J Med Health Sci. 2021;15(4):1535-9. [LINK]

[64] Borges do Nascimento IJ, Harries M, Rocha VB, Thompson JY, Wong CH, Kord Varkaneh H, et al. Effect of oral minoxidil for alopecia: systematic review. Int J Trichology. 2020;12(4):147-55. [DOI: 10.4103/ijt.ijt_19_20] [PMID]

[65] Villani A, Fabbrocini G, Ocampo-Candiani J, Ruggiero A, Ocampo-Garza SS. Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose. J Eur Acad Dermatol Venereol. 2021;35(7):1485-92. [DOI: 10.1111/jdv.17216] [PMID]

[66] Feaster B, Onamusi T, Cooley JE, McMichael AJ. Oral minoxidil use in androgenetic alopecia and telogen effluvium. Arch Dermatol Res. 2023;315(2):201-5. [DOI: 10.1007/s00403-022-02331-5] [PMID]

[67] Gomolin A, Litvinov IV, Netchiporouk E. Oral minoxidil: a possible new therapy for androgenetic alopecia. J Cutan Med Surg. 2020;24(1):88-9. [DOI: 10.1177/1203475419879887] [PMID]

[68] Therianou A, Vincenzi C, Tosti A. How safe is prescribing oral minoxidil in patients allergic to topical minoxidil? J Am Acad Dermatol. 2022;86(2):429-31. [DOI: 10.1016/j.jaad.2020.04.027] [PMID]

[69] Ramírez-Marín HA, Tosti A. Role of oral minoxidil in patterned hair loss. Indian Dermatol Online J. 2022;13(6):729-33. [DOI: 10.4103/idoj.idoj_246_22] [PMID]

[70] Randolph M, Tosti A. Oral minoxidil treatment for hair loss: a review of efficacy and safety. J Am Acad Dermatol. 2021;84(3):737-46. [DOI; 10.1016/j.jaad.2020.06.1009] [PMID]

[71] Williams KN, Olukoga CTY, Tosti A. Evaluation of the safety and effectiveness of oral minoxidil in children: a systematic review. Dermatol Ther (Heidelb). 2024;14(7):1709-27. [DOI: 10.1007/s13555-024-01197-x] [PMID]

[72] Pallotti F, Senofonte G, Pelloni M, Cargnelutti F, Carlini T, Radicioni AF, et al. Androgenetic alopecia: effects of oral finasteride on hormone profile, reproduction and sexual function. Endocrine. 2020;68(3):688-94. [DOI: 10.1007/s12020-020-02219-2] [PMID]

[73] Shapiro J, Kaufman KD. Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss). J Investig Dermatol Symp Proc. 2003;8(1):20-3. [DOI: 10.1046/j.1523-1747.2003.12167.x] [PMID]

[74] Price VH, Menefee E, Sanchez M, Ruane P, Kaufman KD. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. J Am Acad Dermatol. 2002;46(4):517-23. [DOI: 10.1067/mjd.2002.120537]

[75] Laneuville P. Cyclosporin A induced remission of CD4+ T-CLL associated with eosinophilia and fasciitis. Br J Haematol. 1992;80(2):252-4. [DOI: 10.1111/j.1365-2141.1992.tb08909.x] [PMID]

[76] Arif T, Dorjay K, Adil M, Sami M. Dutasteride in androgenetic alopecia: an update. Curr Clin Pharmacol. 2017;12(1):31-5. [DOI: 10.2174/1574884712666170310111125] [PMID]

[77] Aleissa M. The efficacy and safety of oral spironolactone in the treatment of female pattern hair loss: a systematic review and meta-analysis. Cureus. 2023;15(8):e43559. [DOI: 10.7759/cureus.43559]

[78] Burns LJ, De Souza B, Flynn E, Hagigeorges D, Senna MM. Spironolactone for treatment of female pattern hair loss. J Am Acad Dermatol. 2020;83(1):276-8. [DOI: 10.1016/j.jaad.2020.03.087] [PMID]

[79] Sadeghzadeh Bazargan A, Tavana Z, Dehghani A, Jafarzadeh A, Tabavar A, Alavi Rad E, et al. The efficacy of the combination of topical minoxidil and oral spironolactone compared with the combination of topical minoxidil and oral finasteride in women with androgenic alopecia, female and male hair loss patterns: a blinded randomized clinical trial. J Cosmet Dermatol. 2024;23(2):543-51. [DOI: 10.1111/jocd.15979]

[80] Rathnayake D, Sinclair R. Use of spironolactone in dermatology. Skinmed. 2010;8(6):328-32; quiz 333. [LINK]

[81] Alves R, Grimalt R. A review of platelet-rich plasma: history, biology, mechanism of action, and classification. Skin Appendage Disord. 2018;4(1):18-24. [DOI: 10.1159/000477353] [PMID]

[82] Abdin R, Zhang Y, Jimenez JJ. Treatment of androgenetic alopecia using PRP to target dysregulated mechanisms and pathways. Front Med (Lausanne). 2022;9:843127. [DOI: 10.3389/fmed.2022.843127]

[83] Stevens J, Khetarpal S. Platelet-rich plasma for androgenetic alopecia: a review of the literature and proposed treatment protocol. Int J Womens Dermatol. 2019;5(1):46-51. [DOI: 10.1016/j.ijwd.2018.08.004] [PMID]

[84] Lynch MD, Bashir S. Applications of platelet-rich plasma in dermatology: a critical appraisal of the literature. J Dermatolog Treat. 2016;27(3):285-9. [DOI: 10.3109/09546634.2015.1094178]

[85] Li ZJ, Choi HI, Choi DK, Sohn KC, Im M, Seo YJ, et al. Autologous platelet-rich plasma: a potential therapeutic tool for promoting hair growth. Dermatol Surg. 2012;38(7 Pt 1):1040-6. [DOI: 10.1111/j.1524-4725.2012.02394.x] [PMID]

[86] Paichitrojjana A, Paichitrojjana A. Platelet rich plasma and its use in hair regrowth: a review. Drug Des Devel Ther. 2022;16:635-45. [DOI: 10.2147/DDDT.S356858]

[87] Mercuri SR, Paolino G, Di Nicola MR, Vollono L. Investigating the safety and efficacy of platelet-rich plasma (PRP) treatment for female androgenetic alopecia: review of the literature. Medicina (Kaunas). 2021;57(4):311. [DOI: 10.3390/medicina57040311] [PMID]

[88] Gressenberger P, Kopera D. Plättchenreiches Plasma (PRP) zur Behandlung der androgenetischen Alopezie (AGA): ein aktueller Literaturüberblick. Hautarzt. 2022;73(5):353-7. [DOI: 10.1007/s00105-022-04979-6] [PMID]

[89] Pillai JK, Mysore V. Role of low-level light therapy (LLLT) in androgenetic alopecia. J Cutan Aesthet Surg. 2021;14(4):385-91. [DOI: 10.4103/JCAS.JCAS_218_20] [PMID]

[90] Satino JL, Markou M. Hair regrowth and increased hair tensile strength using the HairMax LaserComb for low-level laser therapy. International Journal of Cosmetic Surgery and Aesthetic Dermatology. 2003;5(2):113-7. [DOI: 10.1089/153082003769591209]

[91] Frigo L, Luppi JS, Favero GM, Maria DA, Penna SC, Bjordal JM, et al. The effect of low-level laser irradiation (In-Ga-Al-AsP-660 nm) on melanoma in vitro and in vivo. BMC Cancer. 2009;9:404. [DOI: 10.1186/1471-2407-9-404] [PMID]

[92] Hou A, Cohen B, Haimovic A, Elbuluk N. Microneedling: a comprehensive review. Dermatol Surg. 2017;43(3):321-39. [DOI: 10.1097/DSS.0000000000000924] [PMID]

[93] Dhurat R, Sukesh MS, Avhad G, Dandale A, Pal A, Pund P. A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. Int J Trichology. 2013;5(1):6-11. [DOI: 10.4103/0974-7753.114700] [PMID]

[94] Zhou Y, Jia L, Zhou D, Chen G, Fu Q, Li N. Advances in microneedles research based on promoting hair regrowth. J Control Release. 2023;353:965-74. [DOI: 10.1016/j.jconrel.2022.12.040] [PMID]

[95] Zhou Y, Seo J, Tu S, Nanmo A, Kageyama T, Fukuda J. Exosomes for hair growth and regeneration. J Biosci Bioeng. 2024;137(1):1-8. [DOI: 10.1016/j.jbiosc.2023.11.001] [PMID]

[96] Gupta AK, Renaud HJ, Halaas Y, Rapaport JA. Exosomes: a new effective non-surgical therapy for androgenetic alopecia? Skinmed. 2020;18(2):96-100. [PMID]

[97] Buontempo MG, Alhanshali L, Ide M, Shapiro J, Lo Sicco K. Examining the uncertainties surrounding exosome therapy in androgenetic alopecia: a call for evidence-based practice. J Drugs Dermatol. 2024;23(3):e86-90. [DOI: 10.36849/jdd.7603] [PMID]

[98] Jimenez F, Alam M, Vogel JE, Avram M. Hair transplantation: basic overview. J Am Acad Dermatol. 2021;85(4):803-14. [DOI: 10.1016/j.jaad.2021.03.124] [PMID]

[99] Avram MR, Rogers NE. Hair transplantation for men. J Cosmet Laser Ther. 2008;10(3):154-60. [DOI: 10.1080/14764170701817056] [PMID]

[100] Kerure AS, Deshmukh N, Agrawal S. Challenges in hair transplantation practice as a beginner. Indian J Dermatol Venereol Leprol. 2021;87(2):303-5. [DOI: 10.25259/IJDVL_281_20] [PMID]

[101] Bunagan MJK, Banka N, Shapiro J. Hair transplantation update: procedural techniques, innovations, and applications. Dermatol Clin. 2013;31(1):141-53. [DOI: 10.1016/j.det.2012.08.012] [PMID]

[102] Avram MR, Finney R, Rogers N. Hair transplantation controversies. Dermatol Surg. 2017;43 Suppl 2:S158-62. [DOI: 10.1097/DSS.0000000000001316] [PMID]

[103] Zhou Y, Chen C, Qu Q, Zhang C, Wang J, Fan Z, et al. The effectiveness of combination therapies for androgenetic alopecia: a systematic review and meta-analysis. Dermatol Ther. 2020;33(4):e13741. [DOI: 10.1111/dth.13741] [PMID]

[104] Abdi P, Awad C, Anthony MR, Farkouh C, Kenny B, Maibach HI, et al. Efficacy and safety of combinational therapy using topical minoxidil and microneedling for the treatment of androgenetic alopecia: a systematic review and meta-analysis. Arch Dermatol Res. 2023;315(10):2775-85. [DOI: 10.1007/s00403-023-02688-1] [PMID]

[105] Ohyama M, Vogel JC. Gene delivery to the hair follicle. J Investig Dermatol Symp Proc. 2003;8(2):204-6. [DOI: 10.1046/j.1087-0024.2003.00810.x] [PMID]

[106] Cotsarelis G. The hair follicle as a target for gene therapy. Ann Dermatol Venereol. 2002;129(5 Pt 2):841-4. [LINK]

[107] Jandali S, Low DW. From surgery to pharmacology to gene therapy: the past, present, and future of hair restoration. Ann Plast Surg. 2010;65(4):437-42. [DOI: 10.1097/SAP.0b013e3181d59f60] [PMID]